HopeStage
Back to all studies
RecruitingNCT05814640

Sequenced medication and CBT options for adolescents with depression

About this titleRead the official source — NCT05814640
Medication studyAges 13–18China
The study in practice

Understand this study

Who could participate?

Listed age limits: 13 years to 18 years.

Listed locations
ChongqingSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 20, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
520
Sponsor
First Affiliated Hospital of Chongqing Medical University
Sponsor type
University
Study type
Drug
Intervention type
Behavioural, Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
China
Age range
From 13 Years to 18 Years
Official registry ID
NCT05814640
Official title
Show the full official title

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD): a Pragmatic Clinical Trial

Recruitment & locations

Currently recruiting

Chongqing

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is First Affiliated Hospital of Chongqing Medical University, a university.

Does this study involve medication?

Yes. The study involves medication, including Fluoxetine, Sertraline, Vortioxetine, Duloxetine, Aripiprazole, Lithium Carbonate and Olanzapine.

Who can participate?

Listed age limits: 13 years to 18 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies